Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women
Primary Purpose
Hypertension
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Valsartan 1
Valsartan 80 mg
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Left Ventricular Hypertrophy, Women
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of hypertension
- Women are all postmenopausal
- Must provide written informed consent
Exclusion Criteria:
- Secondary hypertension
- Coronary disease
- Heart failure
- Arterial fibrillation
- Previous myocardial infarction
- Previous stroke
- Malignant disease
- Kidney failure
- Liver failure
- Neoplastic disease
- Severe neurological diseases
- Severe metabolic or organic decompensation
- Refuse to sign the informed consent form
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
postmenopausal hypertensive women
age-matched hypertensive male patients
Arm Description
Outcomes
Primary Outcome Measures
Relative indexes of myocardial remodeling
Cardiac structure (left ventricular mass index in grams for square meter) measurement.
Relative indexes of myocardial remodeling
Cardiac structure (left ventricular mass index in grams for square meter) measurement.
Ambulatory blood pressure monitoring
Non-invasive ambulatory blood pressure monitoring (ABPM) was performed for every enrolled patient with an ABPM equipment.
Ambulatory blood pressure monitoring
Non-invasive ambulatory blood pressure monitoring (ABPM) was performed for every enrolled patient with an ABPM equipment.
Sexual hormones
Blood samples used to analyze the levels of sexual hormones were collected between morning 8:00 and 9:00 after an overnight fast. The sexual hormones which include prolactin (PRL) and progesterone (P) units on nanogram per millilitre, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) units on millionInternationalUnits per millilitre, testosterone (T) in nanogram per deciliter, estradiol (E2) in picogram per millilitre.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03432468
Brief Title
Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women
Official Title
Effect of Fully Blocking Type 1 Angiotensin Receptor on Blood Pressure, Cardiac Structure, Cardiac Function and Cognitive Function in Postmenopausal Hypertensive Women
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Unknown status
Study Start Date
April 1, 2018 (Anticipated)
Primary Completion Date
August 1, 2019 (Anticipated)
Study Completion Date
August 1, 2019 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
LanZhou University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
This study compared the improvements of blood pressure levels, left ventricular hypertrophy, left ventricular diastolic function, vascular function and cognitive function between postmenopausal hypertensive women and age-matched hypertensive male patients through the evaluation of the effects of fully blocked AT1 receptor by valsartan. Additionally, the differences of the above indexes between the patients who were fully blocked AT1 receptor by valsartan and the patients who were treated with a single dose of valsartan treatment were assessed, so as to provide theory basis for clinical treatment of postmenopausal hypertensive women.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, Left Ventricular Hypertrophy, Women
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
102 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
postmenopausal hypertensive women
Arm Type
Active Comparator
Arm Title
age-matched hypertensive male patients
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Valsartan 1
Intervention Description
the high dose of valsartan
Intervention Type
Drug
Intervention Name(s)
Valsartan 80 mg
Intervention Description
a single dose of valsartan
Primary Outcome Measure Information:
Title
Relative indexes of myocardial remodeling
Description
Cardiac structure (left ventricular mass index in grams for square meter) measurement.
Time Frame
Change from Baseline left ventricular mass index at 6 months.
Title
Relative indexes of myocardial remodeling
Description
Cardiac structure (left ventricular mass index in grams for square meter) measurement.
Time Frame
Change from Baseline left ventricular mass index at 12 months.
Title
Ambulatory blood pressure monitoring
Description
Non-invasive ambulatory blood pressure monitoring (ABPM) was performed for every enrolled patient with an ABPM equipment.
Time Frame
Change from Baseline ABPM at 6 months.
Title
Ambulatory blood pressure monitoring
Description
Non-invasive ambulatory blood pressure monitoring (ABPM) was performed for every enrolled patient with an ABPM equipment.
Time Frame
Change from Baseline ABPM at 12 months.
Title
Sexual hormones
Description
Blood samples used to analyze the levels of sexual hormones were collected between morning 8:00 and 9:00 after an overnight fast. The sexual hormones which include prolactin (PRL) and progesterone (P) units on nanogram per millilitre, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) units on millionInternationalUnits per millilitre, testosterone (T) in nanogram per deciliter, estradiol (E2) in picogram per millilitre.
Time Frame
Baseline sexual hormones.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of hypertension
Women are all postmenopausal
Must provide written informed consent
Exclusion Criteria:
Secondary hypertension
Coronary disease
Heart failure
Arterial fibrillation
Previous myocardial infarction
Previous stroke
Malignant disease
Kidney failure
Liver failure
Neoplastic disease
Severe neurological diseases
Severe metabolic or organic decompensation
Refuse to sign the informed consent form
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Learn more about this trial
Effect of Fully Blocking Type 1 Angiotensin Receptor on Target Organ Damage of Postmenopausal Hypertensive Women
We'll reach out to this number within 24 hrs